Research ArticleTheranostics
68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study
Wolfgang Peter Fendler, Jeremie Calais, Martin Allen-Auerbach, Christina Bluemel, Nina Eberhardt, Louise Emmett, Pawan Gupta, Markus Hartenbach, Thomas A. Hope, Shozo Okamoto, Christian Helmut Pfob, Thorsten D. Pöppel, Christoph Rischpler, Sarah Schwarzenböck, Vanessa Stebner, Marcus Unterrainer, Helle D. Zacho, Tobias Maurer, Christian Gratzke, Alexander Crispin, Johannes Czernin, Ken Herrmann and Matthias Eiber
Journal of Nuclear Medicine October 2017, 58 (10) 1617-1623; DOI: https://doi.org/10.2967/jnumed.117.190827
Wolfgang Peter Fendler
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
2Department of Nuclear Medicine, Ludwig-Maximilians-University Munich, Munich, Germany
Jeremie Calais
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
3Department of Nuclear Medicine, Bichat University Hospital, AP-HP, University of Paris VII, Paris, France
Martin Allen-Auerbach
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
Christina Bluemel
4Department of Nuclear Medicine, Julius-Maximilians-University of Würzburg, Würzburg, Germany
Nina Eberhardt
5Department of Nuclear Medicine, Ulm University, Ulm, Germany
Louise Emmett
6Department of Diagnostic Imaging, St. Vincent's Public Hospital, Sydney, Australia, and University of New South Wales, Sydney, New South Wales, Australia
Pawan Gupta
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
Markus Hartenbach
7Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
Thomas A. Hope
8Department of Radiology and Biomedical Imaging, University of California, San Francisco, California
Shozo Okamoto
9Department of Nuclear Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Christian Helmut Pfob
10Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany
Thorsten D. Pöppel
11Department of Nuclear Medicine, Medical Faculty, University Duisburg-Essen, University Hospital Essen, Essen, Germany
Christoph Rischpler
10Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany
Sarah Schwarzenböck
12Department of Nuclear Medicine, Rostock University Medical Centre, Rostock, Germany
Vanessa Stebner
11Department of Nuclear Medicine, Medical Faculty, University Duisburg-Essen, University Hospital Essen, Essen, Germany
Marcus Unterrainer
2Department of Nuclear Medicine, Ludwig-Maximilians-University Munich, Munich, Germany
Helle D. Zacho
13Department of Nuclear Medicine, Aalborg University Hospital, Aalborg, Denmark
Tobias Maurer
14Department of Urology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany
Christian Gratzke
15Department of Urology, Ludwig-Maximilians-University of Munich, Munich, Germany; and
Alexander Crispin
16Institute of Medical Informatics, Biometry, and Epidemiology, Ludwig-Maximilians-University Munich, Germany
Johannes Czernin
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
Ken Herrmann
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
11Department of Nuclear Medicine, Medical Faculty, University Duisburg-Essen, University Hospital Essen, Essen, Germany
Matthias Eiber
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
10Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 58, Issue 10
October 1, 2017
68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study
Wolfgang Peter Fendler, Jeremie Calais, Martin Allen-Auerbach, Christina Bluemel, Nina Eberhardt, Louise Emmett, Pawan Gupta, Markus Hartenbach, Thomas A. Hope, Shozo Okamoto, Christian Helmut Pfob, Thorsten D. Pöppel, Christoph Rischpler, Sarah Schwarzenböck, Vanessa Stebner, Marcus Unterrainer, Helle D. Zacho, Tobias Maurer, Christian Gratzke, Alexander Crispin, Johannes Czernin, Ken Herrmann, Matthias Eiber
Journal of Nuclear Medicine Oct 2017, 58 (10) 1617-1623; DOI: 10.2967/jnumed.117.190827
68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study
Wolfgang Peter Fendler, Jeremie Calais, Martin Allen-Auerbach, Christina Bluemel, Nina Eberhardt, Louise Emmett, Pawan Gupta, Markus Hartenbach, Thomas A. Hope, Shozo Okamoto, Christian Helmut Pfob, Thorsten D. Pöppel, Christoph Rischpler, Sarah Schwarzenböck, Vanessa Stebner, Marcus Unterrainer, Helle D. Zacho, Tobias Maurer, Christian Gratzke, Alexander Crispin, Johannes Czernin, Ken Herrmann, Matthias Eiber
Journal of Nuclear Medicine Oct 2017, 58 (10) 1617-1623; DOI: 10.2967/jnumed.117.190827
Jump to section
Related Articles
Cited By...
- A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy
- A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy
- 68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study
- A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy
- Utility of 18F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology
- aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in 18F-DCFPyL Images of Veterans with Prostate Cancer
- Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective Study
- High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT
- PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study
- Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study
- Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET
- Comparison of 3 Interpretation Criteria for 68Ga-PSMA11 PET Based on Inter- and Intrareader Agreement
- Observer Agreement and Accuracy of 18F-Sodium Fluoride PET/CT in the Diagnosis of Bone Metastases in Prostate Cancer
- Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines
- Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer
- Intention-to-Treat Analysis of 68Ga-PSMA and 11C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery
- 68Ga-PSMA-11 PET/MR Detects Local Recurrence Occult on mpMRI in Prostate Cancer Patients After HIFU
- Prospective, Multisite, International Comparison of 18F-Fluoromethylcholine PET/CT, Multiparametric MRI, and 68Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes
- Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging
- Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer
- Aetna and 68Ga-DOTATATE: A Sequel to "The Injustice of Being Judged by the Errors of Others" (1)
- Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
- Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence
- 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning
- Accuracy in the Eye of the Beholder: Can We Improve Agreement in Prostate Cancer Diagnostics with PSMA PET/CT?